Randomized trial of oral teriflunomide for relapsing multiple sclerosis. - Wikidata - awgldk - TriplyDB

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q48847857

about

Teriflunomide for multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Teriflunomide for multiple sclerosis Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis Teriflunomide for multiple sclerosis Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations The challenge of comorbidity in clinical trials for multiple sclerosis B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases Optimizing treatment success in multiple sclerosis The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Targeting CD8 T-Cell Metabolism in Transplantation Newer therapies for multiple sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial.Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis Multiple sclerosis--new treatment modalities The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence Laquinimod therapy in multiple sclerosis: a comprehensive review Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis Therapeutic decisions in multiple sclerosis: moving beyond efficacy

P2860

Q24186016-76103658-26EC-4AB2-AF0C-32330FF27A76 Q24187126-C4976AE9-BF34-49AB-BE9A-1272A7E37EAB Q24198146-0644B4EA-B4C9-4087-A360-6C9D5F95C5A8 Q24201599-2BE2274A-84B1-4662-A11F-B5859FB63F37 Q24202177-1EFE1DC4-64D1-4735-8D12-61DAB9E9D2B8 Q24564715-34F2233C-5123-41E6-BE57-AA5750AD725C Q26745562-5FFAC801-4D9D-4F14-B223-2058658C170B Q26748229-1E8547D5-8927-42F5-B745-7FBD0CBD2113 Q26752859-9EAB8E58-D74E-473B-9357-C8F51B8497D1 Q26765031-5D8ED8D3-D005-421E-9FD0-DD40D983A145 Q26770664-811938A9-B61B-401C-B0A7-B411DCCDEE68 Q26771821-3F356D08-0C9A-4B3E-93E1-DE0956C09D87 Q26771968-26F78EE7-1D55-4FDC-A4B3-FE2BC4CF14ED Q26773978-655A991A-5F52-4821-AB93-DB43ED6CF1E1 Q26777329-2A0D66F6-7F42-43EB-A332-0BC9AED41B0F Q26777686-2BF64FD9-5E80-4DE8-A4CE-6B52FEA9A6A7 Q26777941-A0D0BC0D-2D3D-4E40-93B4-E36C37BFC862 Q26779900-161D2873-F497-4ABB-B44B-87B619154DAC Q26798434-B651C44C-EBAE-4184-877F-09D44EBBF75E Q26822611-57501ACA-E39F-4EE5-B378-A33E58D00C44 Q26849781-FC215AE1-1258-4A15-8422-DF62258134FB Q26998513-6A953EE1-D207-40C4-BBAF-14CD41024FE9 Q26999417-FFC87AAA-1DF1-4786-96DF-A36F065F96F0 Q27000269-D1CA10BA-73F2-4579-9386-F0EE2F92DDD3 Q27009769-AFD2D799-AB07-4630-B41C-51D9A2D0F825 Q27021147-A8FBD497-CBBB-423B-BB9A-A1E7DCC52C5C Q27307622-D7AEFF68-CCB4-4ACB-B9E3-C94A4B24E5B9 Q27693249-3392F1B9-5DEA-4DC5-85A7-A2476E4A52DB Q28066677-AF4F336E-31EA-49C3-A2D5-0F3B6D6E66DA Q28070118-0C3E4065-E93D-48E2-8F26-3024A40B3D31 Q28072906-48D31B31-A56E-47C0-B8B4-E82E71F54586 Q28073849-10DC49A2-F6FC-44A7-8EC0-ED6BC587633C Q28078299-2F7FD031-1E40-41A4-B3D7-7683E20AE0E0 Q28081636-4A3D8B4E-10DD-4E48-8423-29F35CE13073 Q28081876-923F8952-E5F7-4482-9C4C-53D54B9791AF Q28086844-3E5316DE-CBF6-48EB-81FA-C14C46198C4C Q28087414-A64ACE95-4C43-4C02-A4BB-0C02BB37A685 Q28268596-B28E3223-F018-4C37-81C5-A21F64238549 Q28281816-EE8E8F87-52DE-4E89-9E5F-6E4982D2E56A Q28541039-2EB6DCDB-88DF-431E-956D-305193DFC615

P2860

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q48847857

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@en

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@nl

type

label

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@en

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@nl

prefLabel

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@en

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@nl

P1433

Q48847857-97FBB928-18EB-44EA-8FDC-FB1BC2E1E566

P1476

Q48847857-608EDD04-30CA-41F1-AC96-F625F3B25D1E

P2093

Q48847857-0BC6BC34-DD71-44EA-AFF3-CB46FD9D49CB

Q48847857-34330025-3B95-4FE8-92AE-232501A01256

Q48847857-3EA0A85C-B0AF-4BC6-93B9-4F06003495C2

Q48847857-4C523293-DF7F-4120-A0C5-B9C8BD3F2B81

Q48847857-4FB85409-A6BA-46AA-8287-7D8F399BE5E8

Q48847857-6979386B-F153-4DAB-96D9-FFB07EE57E7A

Q48847857-8551ECF6-10A4-47E8-BA49-69915F95A2C3

Q48847857-A552D53E-1F8F-416B-A62D-DE3437EC456B

Q48847857-EABD279F-3C5D-456F-8705-9FF7BBF4660D

Q48847857-F22611E9-B913-4AF5-89F9-5026DEEC797D

P304

Q48847857-54D744DA-1C81-4862-9408-9CAA40FBDCC4

P31

Q48847857-9A492AE8-2202-4096-9FB7-C2876783BCE9

P356

Q48847857-9739D63D-29C0-45F5-BF22-707A78EBF8A2

P407

Q48847857-8A040FB0-0E52-488B-965A-3D6AB3AA2AFE

P433

Q48847857-84095901-B540-44A0-9FC2-A38B29866986

P478

Q48847857-92A5065A-0622-4053-9EA9-3C301574BF2A

P50

Q48847857-0CCD5FBD-7C6C-437B-9AFA-7587DB86FE1D

Q48847857-BAB1991F-E07D-4F5F-B93F-0551D88D25F3

P577

Q48847857-60A462E2-4132-4D01-BDBC-04A967057812

P698

Q48847857-2DE7D6D1-97A8-4E73-AA24-34DC48BF9C63

P921

Q48847857-DB3D2112-04AB-473A-B5D8-0B058D90A5F1

Q48847857-E8D533AF-4EE2-47C7-92CD-35A5098A66EA

P356

P1433

The New England Journal of Medicine

P1476

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

@en

P2093

Aaron Miller

http://www.w3.org/2001/XMLSchema#string

Christian Confavreux

http://www.w3.org/2001/XMLSchema#string

Hadj Benzerdjeb

http://www.w3.org/2001/XMLSchema#string

Jerry S Wolinsky

http://www.w3.org/2001/XMLSchema#string

Lin Wang

http://www.w3.org/2001/XMLSchema#string

Mark S Freedman

http://www.w3.org/2001/XMLSchema#string

Paul O'Connor

http://www.w3.org/2001/XMLSchema#string

Philippe Truffinet

http://www.w3.org/2001/XMLSchema#string

TEMSO Trial Group

http://www.w3.org/2001/XMLSchema#string

Tomas P Olsson

http://www.w3.org/2001/XMLSchema#string

P304

1293-1303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1014656

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21991951

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis